Header Logo

Connection

Yuki Kageyama to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Yuki Kageyama has written about Prostatic Neoplasms.
Yuki Kageyama
Connection Strength
2.050
Prostatic Neoplasms
  1. Screening of chronic radiation proctitis and colorectal cancer using periodic total colonoscopy after external beam radiation therapy for prostate cancer. Jpn J Clin Oncol. 2021 Aug 01; 51(8):1298-1302.
    View in: PubMed
    Score: 0.401
  2. The processus vaginalis transection method is superior to the simple prophylactic procedure for prevention of inguinal hernia after radical prostatectomy. Int J Clin Oncol. 2016 Apr; 21(2):384-388.
    View in: PubMed
    Score: 0.265
  3. Suppression of mutant androgen receptors by flutamide. Int J Urol. 2009 May; 16(5):516-21.
    View in: PubMed
    Score: 0.171
  4. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Pat Anticancer Drug Discov. 2007 Nov; 2(3):203-11.
    View in: PubMed
    Score: 0.155
  5. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate. 2007 Jun 01; 67(8):799-807.
    View in: PubMed
    Score: 0.150
  6. Transrectal ultrasound-guided transperineal 14-core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol. 2004 Aug; 11(8):613-8.
    View in: PubMed
    Score: 0.124
  7. Peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot-assisted radical prostatectomy. Int J Urol. 2023 06; 30(6):532-538.
    View in: PubMed
    Score: 0.112
  8. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]. Hinyokika Kiyo. 1996 Mar; 42(3):197-9.
    View in: PubMed
    Score: 0.069
  9. Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer. Int J Clin Oncol. 2016 Aug; 21(4):764-772.
    View in: PubMed
    Score: 0.068
  10. [Case of septic shock caused by extended spectrum ?-lactamase producing Escherichia coli after transrectal prostate biopsy, successfully treated by endotoxin adsorption therapy]. Hinyokika Kiyo. 2013 Sep; 59(9):593-6.
    View in: PubMed
    Score: 0.058
  11. Minimum incision endoscopic surgery (MIES) in Japanese urology: results of adrenalectomy, radical nephrectomy and radical prostatectomy. Aktuelle Urol. 2010 Jan; 41 Suppl 1:S15-9.
    View in: PubMed
    Score: 0.045
  12. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int J Urol. 2008 Dec; 15(12):1055-60.
    View in: PubMed
    Score: 0.042
  13. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 01; 68(14):1570-81.
    View in: PubMed
    Score: 0.041
  14. A case of prostatic duct adenocarcinoma: its clinical significance in comparison with typical acinar adenocarcinoma. Hinyokika Kiyo. 2008 Mar; 54(3):243-7.
    View in: PubMed
    Score: 0.040
  15. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6012-7.
    View in: PubMed
    Score: 0.036
  16. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol. 2007 Mar; 51(3):675-82; discussion 682-3.
    View in: PubMed
    Score: 0.035
  17. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int. 2006 Jun; 97(6):1184-9.
    View in: PubMed
    Score: 0.035
  18. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15; 12(10):3003-9.
    View in: PubMed
    Score: 0.035
  19. Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol. 2006 Apr; 11(2):127-32.
    View in: PubMed
    Score: 0.035
  20. TNP-470 combined with nicardipine suppresses in vivo growth of PC-3, a human prostate cancer cell line. Urol Oncol. 2002 Nov-Dec; 7(6):229-34.
    View in: PubMed
    Score: 0.027
  21. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002; 41(3):289-96.
    View in: PubMed
    Score: 0.026
  22. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J. 1997 Aug; 44(4):527-32.
    View in: PubMed
    Score: 0.019
  23. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol. 1997 Jul; 4(4):407-10.
    View in: PubMed
    Score: 0.019
  24. [Outcome of simple prophylactic procedure of inguinal hernia after radical prostatectomy]. Hinyokika Kiyo. 2012 Aug; 58(8):415-20.
    View in: PubMed
    Score: 0.013
  25. Detection of P-glycoprotein in human urogenital carcinomas and its relationship to epidermal growth factor receptor expression. Eur Urol. 1991; 20(1):58-61.
    View in: PubMed
    Score: 0.012
  26. [Urinary bladder tumor manifesting multiple bone metastases similar to prostatic carcinoma--a case report]. Gan No Rinsho. 1988 Jan; 34(1):111-4.
    View in: PubMed
    Score: 0.010
  27. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab. 2004 Jun; 286(6):E927-31.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.